Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Enemeez is an over-the-counter (OTC) mini-enema containing docusate sodium, used primarily for the rapid relief of constipation and as a core component of bowel management programs for individuals with spinal cord injuries or neurological impairments. As a stool-softening surfactant, docusate sodium works by reducing the surface tension of the fecal mass, which facilitates the penetration of water and lipids into the stool. This process softens the stool and eases evacuation. Unlike oral stool softeners that may take 12 to 72 hours to produce results, the Enemeez mini-enema typically induces a bowel movement within 2 to 15 minutes due to its localized rectal administration. The product is marketed by Quest Products.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Enemeez.